This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
Subjects voluntary agreement to provide written informed consent.
Aged 18 to 70 years, either sex.
Adequate organ function meet screening criteria.
Positive test for cluster of differentiation antigen 19 (CD19).
Active infections such as hepatitis and tuberculosis.
Other autoimmune diseases.
Serious underlying diseases such as tumor, uncontrolled diabetes.
Female subjects who were pregnant, breastfeeding.